These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30873380)

  • 1. Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases.
    Hui KF; Yiu SPT; Tam KP; Chiang AKS
    Front Oncol; 2019; 9():81. PubMed ID: 30873380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Advances in EBV Related Lymphoproliferative Diseases.
    Lv K; Yin T; Yu M; Chen Z; Zhou Y; Li F
    Front Oncol; 2022; 12():838817. PubMed ID: 35515118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus.
    Navari M; Fuligni F; Laginestra MA; Etebari M; Ambrosio MR; Sapienza MR; Rossi M; De Falco G; Gibellini D; Tripodo C; Pileri SA; Leoncini L; Piccaluga PP
    Front Microbiol; 2014; 5():728. PubMed ID: 25566237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.
    Hui KF; Tam KP; Chiang AKS
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29160853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
    Hui KF; Chiang AK
    Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders.
    Crombie JL; LaCasce AS
    Front Oncol; 2019; 9():109. PubMed ID: 30899698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
    Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
    mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future.
    Yiu SPT; Dorothea M; Hui KF; Chiang AKS
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32748879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases.
    Kimura H; Fujiwara S
    Front Pediatr; 2018; 6():417. PubMed ID: 30662890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of Epstein-Barr Virus-Infected Lymphocyte Cell Types in Peripheral Blood Mononuclear Cells as a Valuable Diagnostic Tool in Hematological Diseases.
    Zhang P; Zeng C; Cheng J; Zhou J; Gu J; Mao X; Zhang W; Cao Y; Luo H; Xu B; Li Q; Xiao M; Zhou J
    Open Forum Infect Dis; 2019 May; 6(5):ofz171. PubMed ID: 31065564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
    Ye J; Gradoville L; Daigle D; Miller G
    J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
    Leong IT; Fernandes BJ; Mock D
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
    Tse E; Kwong YL
    Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
    Schwartz Z; Bowe RB; Coleman M; Magro CM
    Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Understanding the Pathogenesis of Epstein-Barr Virus-Associated Lymphoproliferative Disorders.
    Yang X; Nishida N; Zhao X; Kanegane H
    Iran J Allergy Asthma Immunol; 2015 Oct; 14(5):462-71. PubMed ID: 26742434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
    Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
    Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Trends and Alternative Scenarios in EBV Research.
    Minarovits J; Niller HH
    Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases.
    Kim WY; Montes-Mojarro IA; Fend F; Quintanilla-Martinez L
    Front Pediatr; 2019; 7():71. PubMed ID: 30931288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.